Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
Synonyms
Ticlopidinum
Ticlopidine hydrochloride
Ticlopidine
Ticlopidina
Brand Names
Mylan-ticlopidine
Ticlid 250mg Tablets
Ticlopidine hydrochloride
Sandoz Ticlopidine
Ticlid Tab 250mg
Ticlopidine
Dom-ticlopidine
Ticlid
Ticlopidine Hydrochloride
Ticlopidine-250
PMS-ticlopidine
Teva-ticlopidine
Alti-ticlopidine - Tab 250mg
Indication
Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
